Tim Lantin
Aging research is rate-limited by long iteration loops; it may take years or decades to know if an intervention has any effect.
Core trick
Compares spaceflight blood transcriptomes against aged human immune signatures at the pathway level, then reverses the signature against LINCS to nominate drugs.
Description
Aging research is rate-limited by long iteration loops; it may take years or decades to know if an intervention has any effect. However, recent research provides evidence that astronauts “exhibit many hallmarks of aging…often on accelerated timelines”, which raises the interesting possibility of spaceflight-as-an-accelerated-aging model. Here, Claude and I investigate three questions:
1. To what extent do the effects of spaceflight resemble the aged human transcriptome?
2. Are these effects reproducible enough to be an accelerated aging model?
3. What existing drugs might reverse these effects?
We reframed open human spaceflight blood transcriptomics as an accelerated model of immune aging. Using OPEN NASA OSDR data only, we found the conserved spaceflight signature most resembles human immune aging (inflammaging), replicating at the pathway level across three independent missions (Inspiration4, Ax-1, JAXA) — different platforms, biofluids, 3 to >120 days. The telomere axis doesn't transfer — reported straight. Reversing the signature against LINCS and cross-filtering against lifespan-extending geroprotectors yields a dual-evidence drug shortlist (taxifolin, everolimus, curcumin) — hypothesis-generating, not clinical advice. Astronauts age fast and recover on a known clock, making spaceflight data a testbed for geroprotectors — the actionable step existing work stops short of.
README excerpt
# Spaceflight as an accelerated model of terrestrial disease Integrated analysis of **open** human spaceflight blood transcriptomics, reframed as a natural accelerated model of terrestrial immune aging. Built for the *Built with Claude: Life Sciences* hackathon (Anthropic × Gladstone). **One-line finding.** The conserved human spaceflight blood signature — reproduced across two independent missions and validated out-of-sample in a mission the SOMA atlas never used — most closely resembles terrestrial **immune aging / inflammaging**, and a **dual-evidence countermeasure screen** (transcriptional reversal × independent lifespan-extension) nominates oral, human-safe geroprotectors that oppose it. ## What is new here SOMA (Overbey et al., *Nature* 2024) **characterized** the conserved spaceflight signature but did not disease-map it or test it in independent commercial missions. Building on that: 1. **Disease-signature mapping** (rank-based GSEA; two confound nulls) → immune-aging resemblance. 2. **Out-of-sample replication** in **Axiom Ax-1** (OSD-903), a mission SOMA did not include. 3. **Dual-evidence countermeasures** → compounds that (a) transcriptionally REVERSE the signature (XSum connectivity over LINCS L1000) AND (b) independently extend lifespan (HAGR DrugAge), ranked by mission-pharmacy feasibility. Top actionable hits: **taxifolin, ursolic acid, curcumin, everolimus**. Hypothesis-generating only — see `docs/countermeasure_report.md`. See `docs/RELATED_W